Cancer-associated thrombosis: What about microRNAs targeting the tissue factor coagulation pathway?

Tavares, Valéria; Neto, Beatriz Vieira; Marques, Inês Soares; Assis, Joana; Pereira, Deolinda; Medeiros, Rui

doi:10.1016/j.bbcan.2023.189053

Cited by 9 publications

(1 citation statement)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inclusively, the overexpression of this coagulation factor in several tumour types, including OC, is linked to poor prognosis [247][248][249][250]. The protumourigenic roles of TF encompass tumour cell proliferation, cancer stemness, angiogenesis, immune evasion, and metastasis through clotting-dependent and independent processes [243,[251][252][253]. Recently, tisotumab vedotin (Tivdak™), a TF-specific human ADC conjugated to the tubulin-targeting agent called monomethyl auristatin E (MMAE), was approved by the FDA for the management of recurrent or metastatic cervical tumour [254][255][256].…”

Section: Coagulation-targeting Approachesmentioning

confidence: 99%

Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements

Tavares,

Marques,

Melo

et al. 2024

IJMS

Self Cite

View full text Add to dashboard Cite

Ovarian cancer (OC) is the female genital malignancy with the highest lethality. Patients present a poor prognosis mainly due to the late clinical presentation allied with the common acquisition of chemoresistance and a high rate of tumour recurrence. Effective screening, accurate diagnosis, and personalised multidisciplinary treatments are crucial for improving patients’ survival and quality of life. This comprehensive narrative review aims to describe the current knowledge on the aetiology, prevention, diagnosis, and treatment of OC, highlighting the latest significant advancements and future directions. Traditionally, OC treatment involves the combination of cytoreductive surgery and platinum-based chemotherapy. Although more therapeutical approaches have been developed, the lack of established predictive biomarkers to guide disease management has led to only marginal improvements in progression-free survival (PFS) while patients face an increasing level of toxicity. Fortunately, because of a better overall understanding of ovarian tumourigenesis and advancements in the disease’s (epi)genetic and molecular profiling, a paradigm shift has emerged with the identification of new disease biomarkers and the proposal of targeted therapeutic approaches to postpone disease recurrence and decrease side effects, while increasing patients’ survival. Despite this progress, several challenges in disease management, including disease heterogeneity and drug resistance, still need to be overcome.

show abstract